Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Oppenheimer raised their FY2019 earnings per share estimates for Outlook Therapeutics in a report issued on Wednesday, September 4th, according to Zacks Investment Research. Oppenheimer analyst L. Gershell now anticipates that the company will earn ($1.63) per share for the year, up from their previous forecast of ($1.95). Oppenheimer also issued estimates for Outlook Therapeutics’ Q4 2019 earnings at ($0.32) EPS, FY2020 earnings at ($1.41) EPS, FY2021 earnings at ($0.26) EPS, FY2022 earnings at $2.26 EPS and FY2023 earnings at $4.43 EPS.
Several other equities analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Outlook Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Tuesday, September 10th. LADENBURG THALM/SH SH assumed coverage on shares of Outlook Therapeutics in a report on Wednesday, September 11th. They set a “buy” rating and a $9.00 price target for the company. ValuEngine raised shares of Outlook Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright assumed coverage on shares of Outlook Therapeutics in a report on Thursday, July 18th. They set a “buy” rating and a $8.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $7.79.
Outlook Therapeutics stock opened at $1.75 on Monday. Outlook Therapeutics has a 12 month low of $0.85 and a 12 month high of $10.96. The company has a market cap of $49.41 million, a PE ratio of -0.16 and a beta of -0.64. The company has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $2.41.
Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. The business had revenue of $0.58 million during the quarter, compared to analyst estimates of $0.73 million.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cormorant Asset Management LP bought a new stake in shares of Outlook Therapeutics during the second quarter valued at about $32,000. Chicago Capital LLC purchased a new position in Outlook Therapeutics in the 2nd quarter worth about $40,000. Finally, Vanguard Group Inc. increased its stake in Outlook Therapeutics by 712.1% in the 2nd quarter. Vanguard Group Inc. now owns 396,001 shares of the company’s stock worth $824,000 after purchasing an additional 347,238 shares in the last quarter. Institutional investors and hedge funds own 2.95% of the company’s stock.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Recommended Story: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Outlook Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outlook Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.